CRANBURY, N.J., Nov. 29, 2016 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a clinical stage, oncology-focused pharmaceutical
"Brian is a highly credentialed clinician scientist with an outstanding track record in personalized medicine and oncology clinical development," said Howard Jonas, Cornerstone's Chairman. "As Cornerstone's Chief Medical Officer, Dr. Mullaney will guide the clinical development of our lead compound, CPI-613, as well as the other promising compounds in our pipeline. Having successfully guided many oncology drugs through clinical trials, Dr. Mullaney will be pivotal in helping us advance a robust R&D pipeline of cutting edge drugs with the potential to considerably improve cancer treatment practices."
Dr. Mullaney's hiring strengthens Cornerstone's drug development and commercialization capabilities, while also continuing the company's recent momentum. On November 10, Cornerstone announced that IDT Corporation (NYSE: IDT) made a $10 million investment in the company. Cornerstone will be making two presentations of new data at the American Society of Hematology 2016 Annual Meeting.
"Cornerstone's focus on targeting the metabolic pathways in cancer cell proliferation and survival holds tremendous promise, and may revolutionize oncology treatment practices," said Dr. Mullaney. "I am excited to join Cornerstone at such an important time in their development. The company's lead compound, CPI-613, has produced impressive preliminary clinical results in patients with advanced pancreatic cancer, acute myeloid leukemia (AML), and T-cell non-Hodgkin's lymphoma (T-cell NHL). As we ramp up our commercialization efforts and prepare to advance CPI-613 into Phase II clinical trials, we will continue to move forward with our deep pipeline of innovative compounds that may usher in a new paradigm in anticancer therapy."
Prior to joining Cornerstone, Dr. Mullaney was the Global Head of Clinical Affairs for Oncology Precision Medicine at Novartis. He has more than 20 years of leadership experience in precision medicine and clinical development including senior positions at Eli Lilly & Co., Bristol-Myers Squibb and Myriad Genetics.
Dr. Mullaney joins Cornerstone's seasoned executive management team, which includes:
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit: www.cornerstonepharma.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Contact: Jacob Jonas Public Relations, Cornerstone Pharmaceuticals, Inc. email@example.com
Kara Golub JFK Communications, Inc. 609-456-0822 firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-appoints-brian-mullaney-md-phd-as-chief-medical-officer-300369481.html
SOURCE Cornerstone Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All